CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
Mark H. O’Hara, Eileen M. O’Reilly, Gauri R. Varadhachary, Robert A. Wolff, Zev A. Wainberg, Andrew H. Ko, George A. Fisher, Osama E. Rahma, Jaclyn P. Lyman, Christopher R. Cabanski, Rosemarie Mick, Pier Federico Gherardini, Lacey J. Kitch, Jingying Xu, Theresa Samuel, Joyson Karakunnel, Justin Fairchild, Samantha Bucktrout, Theresa LaVallee, Cheryl Selinsky, Jacob E. Till, Erica L. Carpenter, Cécile Alanio, Katelyn T. Byrne, Richard O Chen, Ovid Trifan, Ute Dugan, Christine E. Horak, Vanessa M. Hubbard-Lucey, E. John Wherry, Ramy Ibrahim, Robert H. Vonderheide
Topics & Concepts
Monoclonal antibodyNivolumabMetastatic adenocarcinomaAdenocarcinomaMedicineChemotherapyAntibodyAgonistic behaviourOncologyMonoclonalInternal medicineCancer researchImmunotherapyImmunologyCancerPsychiatryAggressionPancreatic and Hepatic Oncology ResearchCancer Immunotherapy and BiomarkersCAR-T cell therapy research